Blog
RSS FeedPosted by Michael Wonder on 21 Nov 2025
US pharma ramps up attack on Australia’s ‘discriminatory’ drug pricing
20 November 2025 - The US pharmaceutical industry is increasing pressure on Donald Trump to take action against the PBS, ...
Posted by Michael Wonder on 21 Nov 2025
Merck Canada and the pan-Canadian Pharmaceutical Alliance successfully complete negotiations for Winrevair (sotatercept)
20 November 2025 - Merck announced that it has successfully completed negotiations with the pan‑Canadian Pharmaceutical Alliance (pCPA) for Winrevair (sotatercept). ...
Posted by Michael Wonder on 20 Nov 2025
Welcoming Natalie McMurtry, Chief Executive of PHARMAC
19 November 2025 - In September Natalie McMurtry joined PHARMAC as our new Chief Executive. ...
Posted by Michael Wonder on 19 Nov 2025
Agenda for the March 2026 PBAC meeting (19 November 2025)
19 November 2025 - The agenda for the March 2026 PBAC meeting is now available. ...
Posted by Michael Wonder on 14 Nov 2025
Outcome statement - DUSC October 2025 meeting
14 November 2025 - The outcome statement from the October 2025 DUSC meeting is now available. ...
Posted by Michael Wonder on 14 Nov 2025
Public Summary Documents (first time decisions not to recommend and deferrals) – July 2025 PBAC meeting
14 November 2025 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the July 2025 PBAC ...
Posted by Michael Wonder on 13 Nov 2025
PHARMAC to fund alternative treatment for tooth decay
12 November 2025 - PHARMAC will fund silver diamine fluoride for the treatment and prevention of tooth decay from 1 December ...
Posted by Michael Wonder on 13 Nov 2025
Cheaper cancer and chronic conditions medicines now on PBS
13 November 2025 - Australians living with cancer and chronic conditions will now have access to life-changing medicine thanks to ...
Posted by Michael Wonder on 12 Nov 2025
SMC - November 2025 decisions
10 November 2025 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...
Posted by Michael Wonder on 12 Nov 2025
PHARMAC to fund five medicines for multiple sclerosis, breast cancer, eye conditions, and lung cancer
12 November 2025 - New Zealanders living with multiple sclerosis, breast cancer, eye conditions, and lung cancer will benefit from ...
Posted by Michael Wonder on 09 Nov 2025
Rhythm Pharmaceuticals announces public reimbursement for Imcivree (setmelanotide) in Canada in five provinces and under the Federal Non-Insured Health Benefits Program
5 November 2025 - Rhythm Pharmaceuticals today announced that it has entered into Product Listing Agreements in the provinces of Ontario, ...
Posted by Michael Wonder on 09 Nov 2025
New cheaper medicine for chronic liver disease
9 November 2025 - Australians living with chronic liver disease will soon have access to a new cheaper medicine on ...
Posted by Michael Wonder on 08 Nov 2025
PHARMAC consults on changes to simplify biologic medicine funding criteria
6 November 2025 - PHARMAC is proposing changes to the Special Authority and Hospital Indication Restrictions criteria for four biologic ...
Posted by Michael Wonder on 07 Nov 2025
Rezurock now covered in Quebec for people living with chronic graft versus host disease
6 November 2025 - Sanofi is pleased to announce that Quebec has added Rezurock (belumosudil tablets) to the list of medications ...
Posted by Michael Wonder on 02 Nov 2025
DoH publishes revised agenda for November 2025 PBAC meeting (version 6)
31 October 2025 - The DoH has published a revised agenda for the November 2025 PBAC meeting. ...